OBI’s Abstract at ASCO 2016: Randomized Phase 2/3 Trial of Active Immunotherapy With OPT-822/OPT-821 in Patients With Metastatic Breast Cancer

Background: Globo H is a glycolipid that is highly expressed in breast cancer (BC). Active immunotherapy with OPT-822, a Globo H-KLH conjugate, and the adjuvant OPT-821 in two phase 1 trials, induced Globo H–specific antibodies which could mediate in vitro binding and cytotoxicity to Globo H expressing BC cells. Methods: In this international, randomized, double-blind, […]

This article is password protected.

To view the content, please enter your password in the field below